
If you're a member: Log-in to get more information about this trial.
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)
ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org